No blended recommendations
A label and a professional guideline may differ. A different formulation or indication may only appear to conflict. Read the complete stored source, its date, renal measure, population and qualifications. These new interpretations remain pending independent clinical review.
Find a review question
Use drug/source terms only, never patient identifiers. Filters are in the URL. No JavaScript is required. CSV includes all matches, not just this page.
279 matching checks; page 27 of 28.
Index identity and monitoring | Added v5.4
Is the release type confirmed and proteinuria monitoring retained?
Tiopronin - THIOLA EC delayed-release 100 mg and 300 mg tablets
The body and dosage-form sections distinguish release types despite inconsistent index labels. Renal guidance emphasizes urinary targets and toxicity monitoring.
What to checkKeep release identity and the proteinuria stop/monitor instruction together.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Index identity and monitoring | Added v5.4
Is the release type confirmed and proteinuria monitoring retained?
Tiopronin - THIOLA immediate-release 100 mg tablets
The body and dosage-form sections distinguish release types despite inconsistent index labels. Renal guidance emphasizes urinary targets and toxicity monitoring.
What to checkKeep release identity and the proteinuria stop/monitor instruction together.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Dose table scope | Added v4.9
Are dose size and dosing frequency being adjusted according to the named source?
Tizanidine - ONTRALFY oral solution
The renal/geriatric discussion favors adjusting individual doses rather than increasing frequency; it does not specify a reduction percentage.
What to checkKeep formulation and geriatric context attached, and avoid inventing a percentage reduction.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Boundary units | Added v4.5
Are the renal measure and actual dialysis clearance assumptions available?
Topiramate - EPRONTIA oral solution
The source uses indexed CrCl, not interchangeable indexed eGFR. It states that a dialysis supplement may be needed without providing a universal dose.
What to checkPreserve the renal measure and dialysis-system assumptions. Do not generate a fixed replacement amount.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Source scope and renal guidance | Added v6.3
Before use: Torsemide - DEMADEX oral tablets?
Torsemide - DEMADEX oral tablets
Reduced tubular delivery may reduce diuretic response; renal disease does not imply a simple proportional dose reduction.
What to checkConfirm the exact product, indication, renal measure and full source before prescribing.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Boundary route and indication | Added v5.4
Are the route, actual body weight, indication and creatinine band all reconciled?
Tranexamic acid - CYKLOKAPRON IV injection
The official renal table repeats an exact creatinine value in adjacent rows. Its doses are scoped to the hemophilia/tooth-extraction indication.
What to checkDo not silently select a row at that boundary, transfer an oral table, or extrapolate to another indication.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Route indication duration | Added v5.4
Is this oral menstrual treatment rather than an IV hemostatic protocol?
Tranexamic acid - LYSTEDA oral tablets
The oral renal bands and treatment duration belong to the menstrual-bleeding product, not the IV indication.
What to checkKeep amount, frequency, course length and contraindications together.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Formulation scope | Added v4.9
Are renal dosing and route-conversion questions being kept separate?
Treprostinil - ORENITRAM extended-release tablets
A small oral dialysis PK study does not replace product-specific titration or transition guidance.
What to checkDo not apply the oral findings to an infused or inhaled schedule.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Evidence limit | Added v4.5
Is the source a dosing recommendation or only an evidence-gap statement?
Triclabendazole - EGATEN
The selected renal subsection supplies an absence-of-study statement, not a tested renal dose or dialysis pathway.
What to checkDo not use this record as an affirmative renal safety clearance; seek applicable product/specialist guidance.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Dose table scope | Added v4.7
Are the renal-specific reduction floor and both daily tablet doses preserved?
Trifluridine/tipiracil (LONSURF)
The severe-impairment pathway has its own reduction floor. A published table band uses unequal morning and evening tablet doses.
What to checkUse the exact BSA row and tablet instructions; do not split the daily total into unavailable or unsupported equal doses.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Before using a source
Confirm exact product and route, indication, age/weight, renal estimate and units, changing renal function, dialysis modality and timing, interacting medicines, monitoring, and the applicable institution's review. A successful page retrieval or a source-count badge establishes none of these on its own.
Clinician interpretation guideReturn to top